Illumina Inc. (ILMN) Director Robert S. Epstein Sells 300 Shares
Illumina Inc. (NASDAQ:ILMN) Director Robert S. Epstein sold 300 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total value of $52,287.00. Following the transaction, the director now directly owns 6,924 shares of the company’s stock, valued at $1,206,783.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Illumina Inc. (NASDAQ:ILMN) opened at 178.45 on Thursday. The company has a 50-day moving average of $170.03 and a 200-day moving average of $153.91. The stock has a market capitalization of $26.16 billion, a price-to-earnings ratio of 61.11 and a beta of 0.73. Illumina Inc. has a one year low of $127.10 and a one year high of $196.47.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.73 by $0.13. The company had revenue of $600 million for the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.80 EPS. On average, equities analysts forecast that Illumina Inc. will post $3.53 EPS for the current fiscal year.
Several research firms have issued reports on ILMN. Zacks Investment Research upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Monday, July 4th. CL King downgraded Illumina from a “buy” rating to a “neutral” rating in a research report on Monday, August 22nd. Piper Jaffray Cos. restated an “overweight” rating and set a $161.00 target price on shares of Illumina in a research report on Friday, July 15th. Vetr downgraded Illumina from a “buy” rating to a “sell” rating and set a $142.96 target price on the stock. in a research report on Tuesday, July 26th. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $165.00 price objective on shares of Illumina in a research report on Thursday, June 2nd. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $163.07.
Institutional investors have recently modified their holdings of the stock. Physicians Financial Services Inc. increased its position in shares of Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock valued at $103,000 after buying an additional 700 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in shares of Illumina during the second quarter worth approximately $112,000. Ropes Wealth Advisors LLC increased its position in shares of Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its position in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. Institutional investors own 95.22% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.